Baricitinib and upadacitinib, as well as the IL-6R inhibitor, sarilumab, constitute novel medications approved by the European Medicine Agency for the treatment of adult patients with moderate to severely active RA with a prior inadequate response or intolerance to methotrexate, with sarilumab demonstrating relatively superior efficacy and safety profile over to JAK inhibitors [28]. The gene discussed is IL6R; the disease is rheumatoid arthritis.